Actinium Grants Inducement Awards to New CFO and BD Chief
New York – October 16, 2026 -- Actinium Pharmaceuticals (NYSE American: ATNM) granted new CFO Matt David, M.D., options on 250,000 shares at $0.97 each, plus 250,000 restricted stock units (RSUs) and up to 75,000 milestone-based RSUs, as inducement for joining the company.
CFO package combines options, time-based RSUs and milestone awards
The October 14, 2026 grant gives Dr. David a non-qualified stock option with a ten-year term. The $0.97 exercise price equals Actinium's closing price on the NYSE American that day.
Twenty-eight percent of the option vests on the first anniversary of the grant. The remainder vests in monthly installments of 2% over the following 36 months.
Of the 250,000 RSUs, 125,000 vest in three equal annual installments on the first, second and third anniversaries. The other 125,000 vest in full on the third anniversary. A further 75,000 RSUs, at most, vest only if specified corporate milestones are met.